108 Denosumab in men with non-metastatic castration-resistant prostate cancer (CRPC) and PSA doubling time (PSADT) ≤6 months
Year: 2013
Type: conference-abstract
Source: European Urology Supplements
Authors: K. Miller, M.R. Smith, D. Dearnaley, L. Dogliotti, B. Egerdie, K. Fizazi, F. Kueppers, L. Montes De Oca, J. Morote, I. Pavlik, P. Sieber, T.L. Tammela, H. Van Poppel, M. Wirth, S. Wong, Z. Ye, A. Braun
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2327280652